Prevention of VTE: Elective Hip or Knee Replacement Surgery: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
Prevention of Stroke and Systemic Embolism: Non-valvular Atrial Fibrillation: ELIQUIS is indicated to reduce the risk of stroke, systemic embolism, and death in patients with non-valvular atrial fibrillation with one or more risk factors, including patients unsuitable for warfarin. Compared to warfarin, ELIQUIS also results in less bleeding, including intracranial hemorrhage.
Treatment of VTE: ELIQUIS is indicated for: treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of recurrent DVT and PE.
Other Services
Country
Account